Fatal borealpox in an immunosuppressed patient treated with antivirals and vaccinia immunoglobulin - Alaska, 2023.

IF 8.2 1区 医学 Q1 IMMUNOLOGY Clinical Infectious Diseases Pub Date : 2024-11-05 DOI:10.1093/cid/ciae536
Julia H Rogers, Benjamin Westley, Thomas Mego, Katherine G Newell, John Laurance, Lisa Smith, Jayme Parker, Sarah Y Park, Shivkumar Venkatasubrahmanyam, Nicholas Noll, Sivan Bercovici, Agam K Rao, Andrea M McCollum, Whitni Davidson, William C Carson, Michael B Townsend, Jeffrey B Doty, Christina Hutson, Yu Li, Kimberly Wilkins, Jiusheng Deng, Crystal M Gigante, Panayampalli S Satheshkumar, Alexandra Tuttle, Julian A Villalba, Julu Bhatnagar, Sarah Reagan-Steiner, Louisa J Castrodale, Joseph B McLaughlin
{"title":"Fatal borealpox in an immunosuppressed patient treated with antivirals and vaccinia immunoglobulin - Alaska, 2023.","authors":"Julia H Rogers, Benjamin Westley, Thomas Mego, Katherine G Newell, John Laurance, Lisa Smith, Jayme Parker, Sarah Y Park, Shivkumar Venkatasubrahmanyam, Nicholas Noll, Sivan Bercovici, Agam K Rao, Andrea M McCollum, Whitni Davidson, William C Carson, Michael B Townsend, Jeffrey B Doty, Christina Hutson, Yu Li, Kimberly Wilkins, Jiusheng Deng, Crystal M Gigante, Panayampalli S Satheshkumar, Alexandra Tuttle, Julian A Villalba, Julu Bhatnagar, Sarah Reagan-Steiner, Louisa J Castrodale, Joseph B McLaughlin","doi":"10.1093/cid/ciae536","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Borealpox virus (BRPV, formerly known as Alaskapox virus) is a zoonotic member of the Orthopoxvirus genus first identified in a person in 2015. In the six patients with infection previously observed BRPV involved mild, self-limiting illness. We report the first fatal BRPV infection in an immunosuppressed patient.</p><p><strong>Methods: </strong>A man aged 69 years from Alaska's Kenai Peninsula was receiving anti-CD20 therapy for chronic lymphocytic leukemia. He presented to care for a tender, red papule in his right axilla with increasing induration and pain. The patient failed to respond to multiple prescribed antibiotic regimens and was hospitalized 65 days postsymptom onset for progression of presumed infectious cellulitis. BRPV was eventually detected through orthopoxvirus real-time polymerase chain reaction testing of mucosal swabs. He received combination antiviral therapy, including 21 days of intravenous tecovirimat, intravenous vaccinia immunoglobulin, and oral brincidofovir. Serial serology was conducted on specimens obtained posttreatment initiation.</p><p><strong>Findings: </strong>The patient's condition initially improved with plaque recession, reduced erythema, and epithelization around the axillary lesion beginning one-week post-therapy. He later exhibited delayed wound healing, malnutrition, acute renal failure, and respiratory failure. He died 138 days postsymptom onset. Serologic testing revealed no evidence the patient generated a humoral immune response. No secondary cases were detected.</p><p><strong>Conclusion: </strong>This report demonstrates that BRPV can cause overwhelming disseminated infection in certain immunocompromised patients. Based on the patient's initial response, early BRPV identification and antiviral therapies might have been beneficial. These therapies, in combination with optimized immune function, should be considered for patients at risk for manifestations of BRPV.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":8.2000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciae536","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Borealpox virus (BRPV, formerly known as Alaskapox virus) is a zoonotic member of the Orthopoxvirus genus first identified in a person in 2015. In the six patients with infection previously observed BRPV involved mild, self-limiting illness. We report the first fatal BRPV infection in an immunosuppressed patient.

Methods: A man aged 69 years from Alaska's Kenai Peninsula was receiving anti-CD20 therapy for chronic lymphocytic leukemia. He presented to care for a tender, red papule in his right axilla with increasing induration and pain. The patient failed to respond to multiple prescribed antibiotic regimens and was hospitalized 65 days postsymptom onset for progression of presumed infectious cellulitis. BRPV was eventually detected through orthopoxvirus real-time polymerase chain reaction testing of mucosal swabs. He received combination antiviral therapy, including 21 days of intravenous tecovirimat, intravenous vaccinia immunoglobulin, and oral brincidofovir. Serial serology was conducted on specimens obtained posttreatment initiation.

Findings: The patient's condition initially improved with plaque recession, reduced erythema, and epithelization around the axillary lesion beginning one-week post-therapy. He later exhibited delayed wound healing, malnutrition, acute renal failure, and respiratory failure. He died 138 days postsymptom onset. Serologic testing revealed no evidence the patient generated a humoral immune response. No secondary cases were detected.

Conclusion: This report demonstrates that BRPV can cause overwhelming disseminated infection in certain immunocompromised patients. Based on the patient's initial response, early BRPV identification and antiviral therapies might have been beneficial. These therapies, in combination with optimized immune function, should be considered for patients at risk for manifestations of BRPV.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2023 年,阿拉斯加,一名接受抗病毒药物和疫苗免疫球蛋白治疗的免疫抑制患者患上致命的伯劳痘。
背景:博拉痘病毒(BRPV,原名阿拉斯加痘病毒)是人畜共患的正痘病毒属成员,2015年首次在一人身上发现。在之前观察到的六名感染患者中,BRPV涉及轻微的自限性疾病。我们报告了首次在免疫抑制患者中发生的致命BRPV感染:一名来自阿拉斯加基奈半岛的 69 岁男子正在接受慢性淋巴细胞白血病的抗 CD20 治疗。他因右侧腋窝出现触痛的红色丘疹并伴有越来越多的压痛而就诊。患者对多种处方抗生素治疗无效,在症状出现 65 天后因推测为感染性蜂窝组织炎恶化而住院治疗。通过对粘膜拭子进行实时聚合酶链反应检测,最终检测出 BRPV。他接受了联合抗病毒治疗,包括 21 天的静脉注射替考韦酯、静脉注射疫苗免疫球蛋白和口服布林昔多福韦。对治疗开始后获得的标本进行了连续血清学检查:治疗一周后,患者的病情开始好转,斑块消退,红斑减轻,腋窝皮损周围上皮脱落。后来,他出现了伤口愈合延迟、营养不良、急性肾功能衰竭和呼吸衰竭等症状。他在发病后 138 天死亡。血清学检测显示,没有证据表明患者产生了体液免疫反应。未发现继发病例:本报告表明,BRPV 可在某些免疫力低下的患者中引起压倒性播散感染。根据该患者的初步反应,早期识别 BRPV 和抗病毒疗法可能是有益的。对于有 BRPV 表现风险的患者,应考虑将这些疗法与优化免疫功能相结合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Infectious Diseases
Clinical Infectious Diseases 医学-传染病学
CiteScore
25.00
自引率
2.50%
发文量
900
审稿时长
3 months
期刊介绍: Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.
期刊最新文献
Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial Efficacy and Safety of Systematic Corticosteroids treatment among HIV-Positive Patients with Tuberculosis: a systematic review and meta-analysis of randomized controlled trials OPAT and Severe Sepsis Mortality. Diagnostic accuracy of TB screening tests in a prospective multinational cohort: Chest-X-ray with computer-aided detection, Xpert TB host response, and C-reactive protein Differences in Trends in Cancer Incidence Rates Among People with HIV during 2001–2019 By Race and Ethnicity and By Risk Group in the United States
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1